• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Ketamine Does Not Alter Brain Reward Processing Five Hours After Infusion

by
November 16, 2026
in Health
Reading Time: 6 mins read
0
Ketamine Does Not Alter Brain Reward Processing Five Hours After Infusion

Ketamine Does Not Alter Brain Reward Processing Five Hours After Infusion

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In a single-blind, placebo-controlled crossover study investigating how racemic ketamine influences motivational brain pathways beyond its acute psychoactive phase, researchers found that a subanesthetic intravenous infusion did not significantly alter neural correlates of reward processing five hours later in healthy volunteers. Published in Translational Psychiatry, the investigation led by researchers at the Medical University of Vienna evaluated 28 healthy adults during functional magnetic resonance imaging while they performed the Monetary Incentive Delay task. While intravenous ketamine produces rapid dissociative and antidepressant effects across differing timelines, its downstream consequences on motivational neurocircuitry have remained poorly understood. The investigators targeted the subacute phase—a transitional window several hours post-administration after dissociative sensations resolve but while molecular plasticity processes are hypothesized to unfold. Neither regional nor whole-brain neuroimaging analyses demonstrated significant drug-related modulation across reward anticipation, loss anticipation, or feedback evaluation, revealing that five hours post-infusion, task-evoked hemodynamic responses in healthy circuitry remained indistinguishable from those under placebo conditions.

Ketamine displays a distinct neuropsychopharmacological profile that differs fundamentally from traditional monoaminergic antidepressant agents, producing clinical improvements within two to four hours that can persist for up to seven days following a single subanesthetic dose. However, its subjective dissociative, psychotomimetic, and sedative effects follow a distinct temporal trajectory, emerging during infusion, peaking within the first hour, and largely resolving within approximately two hours. Prior task-based functional neuroimaging studies in healthy volunteers had primarily examined working memory performance and emotional processing, leaving motivational and reward evaluation pathways comparatively underexplored. Dysfunction in reward anticipation and outcome evaluation represents a core transdiagnostic feature observed across multiple psychiatric conditions, including major depressive disorder, bipolar disorder, schizophrenia, and substance use disorders. Earlier functional neuroimaging investigations had reported conflicting acute alterations within reward-processing regions, such as attenuated ventral striatal activation forty minutes post-infusion in healthy volunteers and elevated striatal responses during feedback two hours post-infusion in remitted depression. Determining whether reward network modulation persists into the subacute window was critical to elucidating ketamine’s chronopharmacology.

To isolate subacute neural effects without confounding clinical symptom variations, the research team recruited right-handed participants aged 18 to 55 years who were in good psychiatric and general medical health. Formal eligibility criteria excluded individuals with current or past psychiatric diagnoses, relevant medical illnesses, substance abuse histories, contraindications to magnetic resonance imaging, or prior ketamine use. A total of 36 participants completed the four-session protocol, which encompassed an initial screening visit, two experimental imaging sessions spaced at least two weeks apart, and a final study completion visit. Following data acquisition, two participants were excluded because of severe motion-related image quality degradation, and additional subjects were omitted due to missing blood concentrations or irregular pharmacokinetic profiles, leaving an analytical sample of 28 participants comprising 15 females and an overall mean age of 23.6 ± 3.8 years. Because one participant lacked complete psychometric questionnaire data, linear mixed-effects models incorporating subjective ratings evaluated 27 subjects.

During each experimental session, participants received an intravenous infusion administered over 40 minutes consisting of either 0.5 mg/kg body weight of racemic ketamine diluted in 0.9% saline solution or an inactive placebo consisting solely of physiological saline. The study maintained a single-blind structure in which participants remained unaware of treatment identity while investigators conducting data acquisition were unblinded. Following infusion cessation, participants were observed within a clinical setting for a minimum of 90 minutes until medically trained staff confirmed full recovery from acute sedative and dissociative manifestations. Participants remained at the research facility under medical supervision until neuroimaging procedures commenced approximately five hours after infusion start, specifically averaging five hours and nine minutes with a standard deviation of six minutes. During this supervised waiting interval, participants engaged exclusively in low-stimulation activities such as light conversation and resting, and consumption was strictly restricted to water and a light meal to preserve experimental control.

While positioned inside a 3 Tesla scanner equipped with a 64-channel head and neck coil, participants performed the Monetary Incentive Delay task, a standardized paradigm evaluating anticipation and outcome phases of reward processing. Across nine randomized blocks lasting ten minutes and five seconds, participants completed 57 discrete trials spanning gain, loss, and neutral conditions with potential financial stakes ranging from 0.50 to 3.00 euros. Each trial began with a cue indicating prospective monetary outcomes, followed after a variable delay by a target stimulus requiring an immediate button press, concluding with immediate feedback displaying the earned outcome and updated balance. Behavioral performance metrics revealed no statistically significant differences between pharmacological conditions: average reaction times were 352 milliseconds under ketamine and 338 milliseconds under placebo, yielding a non-significant paired comparison, while cumulative balances averaged 15.51 euros under ketamine and 15.82 euros under placebo, establishing that motor performance and basic task engagement remained unaffected by prior drug administration.

Serial blood sampling collected at baseline, during infusion, and up to 360 minutes post-infusion mapped systemic drug exposure, with plasma concentrations determined via validated gas chromatography-tandem mass spectrometry. Ketamine levels peaked near the completion of the 40-minute infusion, whereas its primary metabolite, norketamine, accumulated gradually, matching two-compartment pharmacokinetic modeling estimates. In parallel, psychometric evaluations confirmed profound acute subjective effects during active sessions: total scores on the 5-dimensional altered states of consciousness scale were significantly elevated following ketamine administration, averaging 2969.8 compared with 251.6 following placebo. Visual analog scale ratings assessing common adverse symptoms such as dizziness, blurred vision, headache, nausea, dry mouth, poor coordination, and restlessness demonstrated substantial acute elevations immediately post-infusion that subsequently declined by scanning time. However, pre-scan visual analog ratings remained statistically elevated under ketamine, and functional unblinding was substantial, with every responding ketamine participant and 85.7 percent of placebo recipients correctly identifying their administered condition with high confidence.

Preprocessed functional images, corrected for physiological noise, slice timing, head motion, and spatial distortions, entered general linear models evaluating canonical task contrasts including reward anticipation, loss anticipation, success feedback, and failure feedback. Across the entire cohort, the paradigm robustly engaged canonical reward and salience regions, demonstrating robust activation clusters in the ventral and dorsal striatum, anterior insula, supplementary motor area, dorsal anterior cingulate cortex, ventromedial prefrontal cortex, and thalamus. However, second-level whole-brain analyses using flexible factorial modeling and paired t-tests revealed no significant differences in blood-oxygen-level-dependent signal between ketamine and placebo sessions across any canonical contrast at a cluster-level family-wise error threshold of p < 0.05. An exploratory expectation-outcome congruency contrast comparing congruent feedback to incongruent expectancy violations similarly yielded no significant drug effects across the brain, engaging primarily visual occipital regions reflecting visual attention rather than formal reward prediction error computations.

Complementary region of interest analyses targeted anatomically defined bilateral structures central to reward processing, including the striatum, nucleus accumbens, anterior insula, amygdala, and thalamus using the Automated Anatomical Labeling atlas. Linear mixed-effects regressions adjusting for age, sex, measurement session, administration order, subject-specific random intercepts, individual drug exposure area under the curve, and psychometric scores revealed that no drug effect survived false discovery rate correction across any region or contrast. An uncorrected increase in thalamic activation during loss anticipation emerged under ketamine, alongside an uncorrected positive association between subjective consciousness alteration scores and nucleus accumbens activation during loss anticipation. Crucially, individual systemic ketamine exposure quantified via pharmacokinetic area under the curve showed no significant associations with task-evoked hemodynamic responses across any region. Because neither whole-brain nor corrected region of interest analyses demonstrated substance-related divergence, the neuroimaging data indicated that subacute racemic ketamine does not reliably modulate reward circuitry five hours post-administration under these experimental conditions.

Interpreting these null neuroimaging outcomes requires careful consideration of statistical sensitivity and structural study constraints. Post-hoc sensitivity calculations indicated that with 28 participants and six covariates, the experiment possessed 80 percent power to detect repeated-measures effect sizes of approximately f = 0.69 (Cohen’s d = 1.38) at the whole-brain level and f = 0.37 (d = 0.74) within single regions of interest. Consequently, small to moderate physiological modulations cannot be definitively ruled out without formal equivalence testing. Additional methodological limitations included the reliance on visual inspection rather than a priori quantitative framewise displacement cutoffs for motion exclusion, although retrospective frame-displacement comparisons confirmed comparable movement between drug sessions. Furthermore, substantial functional unblinding stemming from unmistakable acute psychotropic sensations could have introduced expectancy biases, while direct circulating levels of secondary metabolites such as hydroxynorketamine were not quantified at the time of scanning. Finally, the investigation evaluated healthy adults free from affective pathology rather than individuals experiencing mood disorders characterized by blunted reward sensitivity.

The research team emphasized that the absence of detectable task-evoked activation changes five hours post-infusion underscores the critical importance of temporal dynamics in ketamine pharmacology. At five hours, parent compound plasma levels have markedly declined following an elimination half-life of two to four hours, acute N-methyl-D-aspartate receptor blockade has largely subsided, and downstream metabolites predominate. The authors hypothesized that ketamine’s most pronounced regulatory actions on reward circuitry may be confined to the acute window within two hours of administration, or may alternatively depend on pre-existing circuit pathology. While ketamine has been shown to normalize blunted frontostriatal connectivity and enhance reward-related responses in depressed cohorts, its effects in healthy brains may operate through different mechanisms or remain undetectable via standard incentive delay paradigms during intermediate windows. The investigators concluded that future research should deploy longitudinal imaging designs featuring dense temporal sampling spanning acute, subacute, and sustained intervals, alongside direct comparisons between clinical and healthy populations, to fully delineate how ketamine alters human motivational circuits over time.

Subject of Research: Subacute neural effects of ketamine on reward processing in healthy adults

Article Title: Subacute effects of ketamine on neural correlates of reward processing

Article References: Briem, E., Stöhrmann, P., Dörl, G., Milz, C., Schlosser, G., Klöbl, M., Reed, M., Atger, M., Schmidt, C., Graf, S., Kathofer, M., Godbersen, G. M., Crone, J. S., Lanzenberger, R., & Spies, M. (2026). Subacute effects of ketamine on neural correlates of reward processing. Translational Psychiatry, 16(1), Article 521. https://doi.org/10.1038/s41398-026-04485-6

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04485-6

Keywords: ketamine, reward processing, Monetary Incentive Delay task, functional magnetic resonance imaging, subacute effects, norketamine, pharmacokinetics, striatum, nucleus accumbens, altered states of consciousness, crossover study, salience processing, dissociative effects, visual analog scale, ventral striatum, neuroimaging

News Source: Cassandra Pierce. (November 16, 2026). Ketamine Does Not Alter Brain Reward Processing Five Hours After Infusion. Scienmag.

Tags: altered states of consciousnesscrossover studydissociative effectsfunctional magnetic resonance imagingketamineMonetary Incentive Delay taskneuroimagingnorketaminenucleus accumbensPharmacokineticsReward Processingsalience processingstriatumsubacute effectsventral striatumvisual analog scale
Share12Tweet7Share2ShareShareShare1

Related Posts

Myocardial Strain Imaging Detects Early Biventricular Dysfunction Across Cirrhosis Stages

Myocardial Strain Imaging Detects Early Biventricular Dysfunction Across Cirrhosis Stages

November 16, 2026
Distinct Migratory Dendritic Cells Cooperate to Prime Resident T Cells in Tumors

Distinct Migratory Dendritic Cells Cooperate to Prime Resident T Cells in Tumors

November 16, 2026

Adding Ociperlimab to Tislelizumab Fails to Improve Advanced Esophageal Cancer Survival

November 16, 2026

Parkinson’s Disease and Kidney Function Share Discrete Genetic Loci Across European Cohorts

November 16, 2026

POPULAR NEWS

  • Fermented Brown Algae Postbiotic Alleviates Vascular Aging Across Multiple Animal Models

    Fermented Brown Algae Postbiotic Alleviates Vascular Aging Across Multiple Animal Models

    29 shares
    Share 12 Tweet 7
  • Myocardial Strain Imaging Detects Early Biventricular Dysfunction Across Cirrhosis Stages

    29 shares
    Share 12 Tweet 7
  • Distinct Migratory Dendritic Cells Cooperate to Prime Resident T Cells in Tumors

    29 shares
    Share 12 Tweet 7
  • Adding Ociperlimab to Tislelizumab Fails to Improve Advanced Esophageal Cancer Survival

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Fermented Brown Algae Postbiotic Alleviates Vascular Aging Across Multiple Animal Models

Myocardial Strain Imaging Detects Early Biventricular Dysfunction Across Cirrhosis Stages

Distinct Migratory Dendritic Cells Cooperate to Prime Resident T Cells in Tumors

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.